mTOR & Autophagy Modulators (Rapamycin)

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: mTOR & Autophagy Modulators (Rapamycin) - References

---

1. Pharmacodynamics & Mechanism of Action

The Mechanistic Target of Rapamycin (mTOR) is a conserved $289\text{ kDa}$ serine/threonine phosphatidylinositol 3-kinase-related kinase (PIKK) that integrates nutrient availability (leucine/arginine via Sestrin2/CASTOR1), growth factors (insulin/IGF-1 via PI3K/Akt/TSC1-2), and cellular energy (AMPK). While essential for developmental growth, chronic post-reproductive mTOR hyperfunction (Mikhail Blagosklonny’s Hyperfunction Theory of Aging) drives cellular hypertrophy, senescence-associated secretory phenotype (SASP), stem cell exhaustion, and proteostatic failure.

• Selective Allosteric mTORC1 Inhibition: Rapamycin (Sirolimus) and its hydroxyethyl derivative Everolimus (RAD001) bind the intracellular immunophilin FKBP12; this binary complex binds the FKBP12-Rapamycin-Binding (FRB) domain of mTOR Complex 1 (mTORC1) (Raptor-containing complex), allosterically blocking substrate access:
  1. Translational Fidelity: Suppresses p70S6 Kinase 1 (S6K1) and 4E-BP1 phosphorylation, shifting ribosomes from rapid, error-prone cap-dependent translation toward high-fidelity stress-response chaperone synthesis.
  2. Autophagy & Mitophagy Disinhibition: Releases mTORC1’s inhibitory phosphorylation of ULK1 ($\text{Ser}757$) and TFEB (Transcription Factor EB), driving nuclear translocation of TFEB, lysosomal biogenesis, clearance of misfolded protein aggregates ($\alpha$-synuclein, tau, lipofuscin), and PINK1/Parkin mitophagy.
  3. SASP & Inflammaging Suppression: Selectively suppresses NF-$\kappa$B-driven translation of IL-1$\alpha$ and IL-6 in senescent cells (acting as a senomorphic agent).
• The mTORC1 vs. mTORC2 Paradox (Why Intermittent Pulsing is Mandatory):
  • mTORC1 is acutely sensitive to nanomolar Rapamycin ($K_i\approx 0.1\text{–}0.5\text{ nM}$).
  • mTORC2 (Rictor-containing complex) is structurally insensitive to acute FKBP12-rapamycin binding; however, chronic daily exposure sequesters free nascent mTOR subunits, preventing de novo assembly of mTORC2. Because mTORC2 phosphorylates Akt ($\text{Ser}473$) to mediate hepatic insulin signaling and T-cell survival, chronic mTORC2 inhibition causes true immunosuppression, pseudo-diabetes (insulin resistance), hyperlipidemia, and aphthous stomatitis.
  • Intermittent Pulsed Dosing ($1\times$ every 7–14 days) inhibits mTORC1 for $48\text{–}72\text{ hours}$ to trigger autophagy and hematopoietic stem cell (HSC) rejuvenation, then allows trough levels to clear ($<1.0\text{ ng/mL}$) before mTORC2 assembly is compromised.

---

2. Pharmacokinetics & Rapalog Comparison

Compound	Elimination $t_{1/2}$	Oral Bioavailability	CYP3A4 / P-gp Interaction	Advantages for Longevity Pulsing
Sirolimus (Rapamune tablet)	$62\text{–}68\text{ hours}$	$14\text{–}18\%$ (nanocrystal tablet; compounded capsules have $<5\%$ bioavailability unless enteric-coated)	High (CYP3A4 & P-gp substrate)	Gold-standard NIA ITP lifespan data; requires 7–10 days for complete trough washout
Everolimus (RAD001)	$28\text{–}30\text{ hours}$	$\sim 20\%$	High (CYP3A4 substrate)	$2\times$ faster washout; reaches zero trough by day 5–6, minimizing mTORC2 spillover on a weekly schedule

Compounded vs. Commercial Tablet Alert

Uncoated compounded sirolimus powder capsules undergo $>80\%$ gastric acid hydrolysis before reaching the duodenum. Always verify commercial nanocrystal tablets (Rapamune/generic Dr. Reddy’s/Zydus) or confirm via 2-hour peak ($C_{\max }$) and 48-hour whole-blood LC-MS/MS sirolimus assay. Grapefruit juice (furanocoumarins) inhibits intestinal CYP3A4 and increases sirolimus AUC by $+250\text{–}350\%$—never combine unpredictably.

---

3. Dosing, Cycling & Synergies

• Standard Longevity Protocol:
  • Sirolimus (Rapamycin): $4\text{–}6\text{ mg}$ orally once weekly (or $8\text{–}10\text{ mg}$ once every 10–14 days) with a light fat-containing breakfast (increases AUC by $+35\%$ while blunting peak $C_{\max }$).
  • Everolimus: $5\text{ mg}$ orally once weekly (mimicking the Mannick et al. human immunosenescence reversal protocol).
• Periodization with Resistance Training: Separate the weekly Rapamycin dose by $\ge 24\text{–}36\text{ hours}$ from your heaviest hypertrophy training session (e.g., take Rapamycin on a rest/cardio/mobility day) so acute mTORC1-mediated myofibrillar protein synthesis is not blunted.
• Synergies: AMPK & Glycemic Agents (Metformin, Berberine, Acarbose) (Metformin, Acarbose, or SGLT2 inhibitors completely abrogate rapamycin-induced gluconeogenesis and lipid shifts; in the NIA Interventions Testing Program, Rapamycin + Acarbose produced the largest mammalian lifespan extension ever recorded: $+29\%$ median in males, $+34\%$ in females).
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Active bacterial/fungal infection, upcoming surgery or acute wound healing (stop $\ge 2\text{ weeks}$ before and after surgery; mTORC1 is required for fibroblast proliferation), active herpes simplex/zoster tendency, pregnancy/fertility attempts (reversibly suppresses spermatogenesis at daily high doses). Discontinue or widen interval if aphthous mouth ulcers (stomatitis) appear.
  • Biomarkers: Whole-Blood Sirolimus Trough Level (LC-MS/MS) drawn immediately prior to the next weekly dose (target: $<0.5\text{–}1.0\text{ ng/mL}$, confirming zero accumulation), CBC with Differential (monitor ANC, ALC, and MCV—a slight drop in RBC MCV is a classic pharmacodynamic marker of mTORC1 engagement), ApoB / Triglycerides, Fasting Insulin & HbA1c, and hs-CRP.

---

4. Key Scientific Evidence Summary

• NIA ITP Late-Life Lifespan Extension: Harrison et al. (2009) published in Nature that feeding Rapamycin to genetically heterogeneous mice starting late in life (600 days old $\approx 60$ human years) extended maximal and median remaining life expectancy by $+28\%$ in males and $+38\%$ in females.
• Human Elderly Immune Rejuvenation RCT: Mannick et al. (2014, 2018) demonstrated in Science Translational Medicine ($N=218$ and $N=264$) that 6 weeks of low-dose intermittent mTORC1 inhibition (RAD001 / Everolimus $0.5\text{ mg/day}$ or $5\text{ mg/week}$) in adults aged $\ge 65$ enhanced influenza vaccine antibody titers by $+20\%$, downregulated PD-1 on exhausted ${\text{CD4}}^{+}/{\text{CD8}}^{+}$ T-cells, and reduced respiratory tract infections over the subsequent year by $-40\text{ to }-52\%$.
• Rapamycin + Acarbose Synergy: Strong et al. (2022) demonstrated in Aging Cell that combining Rapamycin and Acarbose starting at 9 months extended median mouse lifespan by $+29\%$ in males and $+34\%$ in females.

See full study breakdowns in mTOR & Autophagy Modulators (Rapamycin) - References.